Icon
+91 94997 68112
Login Register

Prolia and Xgeva - (60mg/mL, 70mg/mL; Injection, Subcutaneous)

Denosumab Amgen
60mg/mL, 70mg/mL; Injection, Subcutaneous
More Than $1000 mn
None
Less Than 5
None None
None None
Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Xgeva is a RANK ligand (RANKL) inhibitor indicated for Prevention of skeletal-related events in patients with bone metastases from solid tumors
Yes
(*** ******) ****** (****/**) *** ***** (****/**) ******* *** **** ******** *** ******** ***** ********* ***** *** ********* ***********. ****** (******** **** ******** *** *** ***************) *** *** ***** ** **** ** **** *** *** *********. ***** ** ***** *** ****** *** ****** *** $***** *** **** ** ***** *** $*****. ********* ** ***** *** ******, ******** ****** *** ****** *** ***** ******* ** *** **, ****
Prolia and Xgeva Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20 Patent 21 Patent 22 Patent 23
****** ******* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *******/*********** ********** **** ** *** **, ****
  1. *** **, **** : ****** ******** ***** ** ***** **** ******.
  2. *** *, **** : ***** **** ****** **** ************ ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, ’***, ’***, ’***, *** ’***.
  3. *** **, **** : ***** *** ****** **** ******* ********** **** ************ ** ****** '***. ****** ****** ******** *** ************ ** **.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.